Understanding the link between Non-Alcoholic Fatty Liver Disease (NAFLD) and cardiovascular disease is essential. Shared risk factors like obesity and diabetes contribute to both. Pharmaceutical ...

How Should We Manage Patients With Non-alcoholic Fatty Liver Disease in 2007 ... (which results in more energy expenditure), has been shown to stimulate lipid-lipoprotein metabolism in fatty liver.

The use of lipid lowering agents is another treatment approach and is to treat hyperlipidemia in NAFLD. Some lipid-modulating agents include: Clofibrate (fibric acid), Gemfibrozil (fibric acid ...

Non-alcoholic fatty liver disease (NAFLD), characterized by excessive hepatic lipid accumulation, poses a high prevalence and can progress to cirrhosis and liver cancer. To enhance preventive and ...

Further analysis showed that Asah1 deficiency increased harmful lipids accumulation, disrupted lipid metabolism, triggered cellular stress, and impaired the cell's waste disposal system.

Nonalcoholic fatty liver disease (NAFLD), also called steatosis, ... Also the key role of PPARα, a transcription factor involved in controlling glucose and lipid metabolism, ...

Hepatocyte-specific Asah1 gene deletion aggravates Paigen diet (PD)–induced steatosis and injury in mice liver. Credit: The American Journal of Pathology (2024). DOI: 10.1016/j.ajpath.2024.11.003 ...